US2012022034A1PendingUtilityA1

Methods for reducing or neovascularization or edema

63
Individually held — no corporate assignee on recordPriority: Nov 29, 2000Filed: Sep 21, 2011Published: Jan 26, 2012
Est. expiryNov 29, 2020(expired)· nominal 20-yr term from priority
Inventors:Vernon G. Wong
A61P 41/00A61P 43/00A61P 9/00A61P 37/06A61P 27/02A61P 27/00A61K 9/1647A61L 2300/41A61L 2300/222A61K 9/1641A61L 27/54A61K 31/56A61K 31/715A61K 31/765A61F 9/0008A61K 31/573A61F 2210/0004A61L 2300/604A61K 45/06A61L 2300/416A61K 9/0051A61K 47/34A61K 9/0048A61F 9/0017
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

Claims

exact text as granted — not AI-modified
1 . A solid bioerodible implant for reducing or preventing transplant rejection in an eye of an individual, the implant comprising about 50% by weight of dexamethasone and about 50% by weight of polylactic polyglycolic acid (PLGA). 
     
     
         2 . A solid bioerodible implant for reducing or preventing transplant rejection in an eye of an individual, the implant comprising about 70% by weight of dexamethasone and about 30% by weight of polylactic polyglycolic acid (PLGA). 
     
     
         3 . A solid bioerodible implant for reducing or preventing transplant rejection in an eye of an individual, the implant comprising about 50% by weight of dexamethasone, about 15% by weight of hydroxypropyl methylcellulose (HPMC), and about 35% by weight of Resomer RG 502H PLGA. 
     
     
         4 . A solid bioerodible implant for reducing or preventing transplant rejection in an eye of an individual, the implant comprising about 60% by weight of dexamethasone, about 30% by weight of Resomer RG 502H PLGA, and about 10% by weight of Resomer RG 502 PLGA.

Join the waitlist — get patent alerts

Track US2012022034A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.